Argitalpenak (26) Víctor Manuel Sánchez Merino argitalpenak

2024

  1. The Association of HIV-1 Neutralization in Aviremic Children and Adults with Time to ART Initiation and CD4+/CD8+ Ratios

    Vaccines, Vol. 12, Núm. 1

2022

  1. Evaluation of the Thermal Stability of a Vaccine Prototype Based on Virus-like Particle Formulated HIV-1 Envelope

    Vaccines, Vol. 10, Núm. 4

  2. Potent Induction of Envelope-Specific Antibody Responses by Virus-Like Particle Immunogens Based on HIV-1 Envelopes from Patients with Early Broadly Neutralizing Responses

    Journal of Virology, Vol. 96, Núm. 1

2020

  1. Permanent control of HIV-1 pathogenesis in exceptional elite controllers: a model of spontaneous cure

    Scientific Reports, Vol. 10, Núm. 1

2018

  1. Guiding the humoral response against HIV-1 toward a MPER adjacent region by immunization with a VLP-formulated antibody-selected envelope variant

    PLoS ONE, Vol. 13, Núm. 12

2017

  1. Lipid raft-like liposomes used for targeted delivery of a chimeric entry-inhibitor peptide with anti-HIV-1 activity

    Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 13, Núm. 2, pp. 601-609

2016

  1. Antibody-based preventive and therapeutic strategies against HIV

    Current HIV Research, Vol. 14, Núm. 3, pp. 260-269

  2. Definition of an 18-mer Synthetic Peptide Derived from the GB virus C E1 Protein as a New HIV-1 Entry Inhibitor

    Biochimica et Biophysica Acta - General Subjects, Vol. 1860, Núm. 6, pp. 1139-1148

  3. Detection of broadly neutralizing activity within the first months of HIV-1 infection

    Journal of Virology, Vol. 90, Núm. 11, pp. 5231-5245

2015

  1. HIV-1 dual infected LTNP-EC patients developed an unexpected antibody cross-neutralizing activity

    PLoS ONE, Vol. 10, Núm. 8

2014

  1. HIV-1 inhibiting capacity of novel forms of presentation of GB virus C peptide domains is enhanced by coordination to gold compounds

    Current Medicinal Chemistry, Vol. 21, Núm. 2, pp. 238-250

2013

  1. Evolution of broadly cross-reactive HIV-1-neutralizing activity: Therapy-associated decline, positive association with detectable viremia, and partial restoration of B-cell subpopulations

    Journal of Virology, Vol. 87, Núm. 22, pp. 12227-12236

  2. Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions

    Journal of Translational Medicine, Vol. 11, Núm. 1

  3. Influenza, but not HIV-specific CTL epitopes, elicits delayed-type hypersensitivity (DTH) reactions in HIV-infected patients

    European Journal of Immunology, Vol. 43, Núm. 6, pp. 1545-1554

2012

  1. Low-replicating viruses and strong anti-viral immune response associated with prolonged disease control in a superinfected HIV-1 LTNP elite controller

    PLoS ONE, Vol. 7, Núm. 2

2011

  1. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia

    Journal of Virology, Vol. 85, Núm. 12, pp. 5804-5813

  2. Definition of the viral targets of protective HIV-1-specific T cell responses

    Journal of Translational Medicine, Vol. 9, Núm. 1

  3. Human immunodeficiency virus type 1 and related primate lentiviruses engage clathrin through Gag-Pol or gag

    Journal of Virology, Vol. 85, Núm. 8, pp. 3792-3801

2010

  1. Programmed death-1 expression on epstein barr virus specific CD8+ T Cells varies by stage of infection, epitope specificity, and T-cell receptor usage

    PLoS ONE, Vol. 5, Núm. 9

2009

  1. Identification of ongoing human immunodeficiency virus type 1 (HIV-1) replication in residual viremia during recombinant HIV-1 poxvirus immunizations in patients with clinically undetectable viral loads on durable suppressive highly active antiretroviral therapy

    Journal of Virology, Vol. 83, Núm. 19, pp. 9731-9742